Literature DB >> 12692042

Tegaserod and IBS: a perfect match?

W Grant Thompson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12692042      PMCID： PMC1773631          DOI： 10.1136/gut.52.5.621

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  12 in total

1.  Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.

Authors:  T Poynard; C Regimbeau; Y Benhamou
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

2.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

3.  Quantification of the placebo response in ulcerative colitis.

Authors:  A Ilnyckyj; F Shanahan; P A Anton; M Cheang; C N Bernstein
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

Review 4.  Treatment of irritable bowel syndrome: a review of randomised controlled trials.

Authors:  R Akehurst; E Kaltenthaler
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 5.  Gender differences in irritable bowel syndrome.

Authors:  Lin Chang; Margaret M Heitkemper
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

Review 6.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

7.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 8.  Controlled treatment trials in the irritable bowel syndrome: a critique.

Authors:  K B Klein
Journal:  Gastroenterology       Date:  1988-07       Impact factor: 22.682

Review 9.  The treatment of irritable bowel syndrome.

Authors:  W G Thompson
Journal:  Aliment Pharmacol Ther       Date:  2002-08       Impact factor: 8.171

10.  A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Authors:  J Novick; P Miner; R Krause; K Glebas; H Bliesath; G Ligozio; P Rüegg; M Lefkowitz
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171
View more
  1 in total

Review 1.  Tegaserod for the Treatment of Irritable Bowel Syndrome.

Authors:  Valentina Noemi Madia; Antonella Messore; Francesco Saccoliti; Valeria Tudino; Alessandro De Leo; Daniela De Vita; Martina Bortolami; Luigi Scipione; Ivano Pindinello; Roberta Costi; Roberto Di Santo
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.